Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd (DRREDDY) last traded at ₹1,182, a market capitalisation of ₹98,638 crore, on a P/E of 30.6. Over the past 52 weeks the stock has ranged between ₹1,080 and ₹1,415. Dr Reddys Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹8,100 crore and net profit of ₹436 crore. Figures are as of 25 Aug 2026 and are not real time.
Dr Reddys Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Dr Reddys Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹8,100 cr, down 5.5% from ₹8,572 cr a year earlier. Net profit was ₹436 cr, down 69.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 |
| Expenses | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 |
| Operating profit | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 |
| OPM % | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% |
| Other income | 314 | 154 | 528 | 290 | 330 | 271 | 480 | 356 |
| Interest | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 |
| Depreciation | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 |
| Profit before tax | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 | 1,543 | 200 | 553 |
| Tax % | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% |
| Net profit | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 |
| EPS (₹) | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 | 14.50 | 2.65 | 5.32 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Dr Reddys Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 | 33,228 |
| Operating profit | 3,874 | 3,768 | 6,470 | 7,933 | 8,547 | 6,454 | 5,140 |
| OPM % | 20% | 17% | 26% | 28% | 26% | 19% | 15% |
| Net profit | 1,952 | 2,182 | 4,507 | 5,578 | 5,725 | 4,158 | 3,183 |
| EPS (₹) | 23.47 | 26.23 | 54.14 | 66.87 | 67.77 | 50.27 | 38.61 |
TTM is the trailing twelve months to the most recent quarter.
Dr Reddys Laboratories Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 12%
- 3 Years
- 11%
- TTM
- -1%
- 10 Years
- 7%
- 5 Years
- 15%
- 3 Years
- -4%
- TTM
- -43%
- 10 Years
- 7%
- 5 Years
- 6%
- 3 Years
- 1%
- 1 Year
- -7%
- 10 Years
- 15%
- 5 Years
- 16%
- 3 Years
- 16%
- Last Year
- 11%
Dr Reddys Laboratories Ltd shareholding pattern
Promoters held 26.63% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.67% and DIIs 31.75%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.63% | 26.63% |
| FIIs | 27.53% | 26.85% | 25.75% | 25.33% | 24.69% | 22.34% | 21.14% | 20.67% |
| DIIs | 21.48% | 22.89% | 25.63% | 26.73% | 27.99% | 30.44% | 30.72% | 31.75% |
| Public | 24.20% | 23.46% | 21.69% | 21.04% | 20.45% | 20.33% | 21.27% | 20.76% |
| No. of shareholders | 3,10,403 | 4,03,669 | 4,59,605 | 4,51,929 | 4,49,216 | 4,55,243 | 4,49,665 | 4,46,086 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Dr Reddys Laboratories Ltd corporate filings
- Copies of newspaper publicationCompany Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has released copies of newspaper advertisements as part of its…
Read the full analysis - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual FundInsider Trading / SASTlow impact
Cruxal's analysis: ICICI Prudential Mutual Fund has acquired 7,12,884 equity shares of Dr. Reddy's…
Read the full analysis - Change in Senior Management PersonnelCompany Updatemedium impact
Cruxal's analysis: Dr. Reddy's Laboratories Limited has formally disclosed the resignation of Mr. Deepak…
Read the full analysis - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105Company Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105Company Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Dr. Reddy's Laboratories has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Dr Reddys Laboratories Ltd
Cruxal reads every Dr Reddys Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.